Asset Details
Do you wish to reserve the book?
Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation
Do you wish to request the book?
Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation
2013
Overview
Mycolactone is a diffusible lipid secreted by the human pathogen Mycobacterium ulcerans, which induces the formation of open skin lesions referred to as Buruli ulcers. Here, we show that mycolactone operates by hijacking the Wiskott-Aldrich syndrome protein (WASP) family of actin-nucleating factors. By disrupting WASP autoinhibition, mycolactone leads to uncontrolled activation of ARP2/3-mediated assembly of actin in the cytoplasm. In epithelial cells, mycolactone-induced stimulation of ARP2/3 concentrated in the perinuclear region, resulting in defective cell adhesion and directional migration. In vivo injection of mycolactone into mouse ears consistently altered the junctional organization and stratification of keratinocytes, leading to epidermal thinning, followed by rupture. This degradation process was efficiently suppressed by coadministration of the N-WASP inhibitor wiskostatin. These results elucidate the molecular basis of mycolactone activity and provide a mechanism for Buruli ulcer pathogenesis. Our findings should allow for the rationale design of competitive inhibitors of mycolactone binding to N-WASP, with anti-Buruli ulcer therapeutic potential.
Publisher
American Society for Clinical Investigation
Subject
/ Actin Cytoskeleton - metabolism
/ Actin-Related Protein 2-3 Complex
/ Actin-Related Protein 2-3 Complex - metabolism
/ Actins
/ Animals
/ Bacterial Toxins - pharmacology
/ Humans
/ Keratinocytes - drug effects
/ Kinases
/ Mice
/ Propanolamines - pharmacology
/ Proteins
/ Ulcers
/ Wiskott-Aldrich Syndrome Protein Family
/ Wiskott-Aldrich Syndrome Protein Family - antagonists & inhibitors
/ Wiskott-Aldrich Syndrome Protein Family - metabolism
/ Wiskott-Aldrich Syndrome Protein, Neuronal
/ Wiskott-Aldrich Syndrome Protein, Neuronal - antagonists & inhibitors
